DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Papillon-Lefèvre syndrome — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePapillon-Lefèvre syndrome maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for papillon-lefèvre syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
cathepsin C (CTSC) — CTSC is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 3r,5sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 3PDF · 1.85 Å · ligand 2,5-dibromo-N-{(3R,5S)-1-[(Z)-iminomethyl]-5-methylpyrrolidin-3-yl}benzenesulfonamide (LXV). Experimental structure, not a prediction.
What the evidence adds up to
Two siblings with Papillon-Lefèvre syndrome showed no evidence of systemic disease on clinical laboratory tests, including screening for inborn errors of metabolism. Immunological surveys, covering lymphocyte transformation tests with mitogens and polymorphonuclear leukocyte chemotaxis studies, found no disturbance in immune function or host defence mechanisms. A 26-year-old patient whose parents were consanguineous received oral aromatic retinoid for six weeks, which produced nearly total healing of cutaneous lesions. That same patient suffered pronounced bacterial infections throughout life, and a final severe infection led rapidly to death. Chemotactic factors in the blood serum were reduced.
The syndrome is a rare autosomal recessive trait characterised by erythematous palmoplantar hyperkeratosis, early-onset periodontitis, and calcification of the dura mater. A genetic defect has been mapped to chromosome 11q14-q21, involving mutations of cathepsin C. Two cases were diagnosed on the basis of clinical presentation and genetic mapping. A 23-year-old female patient presented with hyperkeratotic plaques on palms and soles, severe periodontal loss, and precocious shedding of both primary and permanent teeth; the reason for this presentation remains vague and speculative.
The 1982 study found no immunological disturbance, yet the 2009 report noted reduced chemotactic factors and fatal infection. The retinoid treatment healed skin lesions but did not prevent death from infection. No controlled trial has tested any drug for survival or periodontal outcomes. What is missing is a prospective trial with sufficient sample size, standardised retinoid dosing, and long-term infection monitoring, as well as genetic stratification by cathepsin C mutation type.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Journal of Periodontal Research · 1982 · 47 citations
Immunological and metabolical studies in two siblings with Papillon‐Lefevre syndrome
AbstractTwo cases of typical Papillon‐Lefevre syndrome in one family were reported. Neither patient showed evidence of systemic disease as assessed by the medical history and a battery of clinical laboratory tests including a screening system for the detection of inborn errors of metabolism. A survey of the patients’ immunological status, including lymphocyte transformation tests using mitogens and polymorphonuclear leukocyte chemoiaxis studies, gave no indication of disturbances in immunological functions and host defense mechanisms. Possible pathogenetic mechanisms are discussed.
AbstractWe report a case of Papillon-Lefèvre syndrome in a patient aged 26 in whom the familial genetic study showed close consanguinity among the parents. Oral treatment with aromatic retinoid during 6 weeks provided nearly total healing of the cutaneous lesions. Among the explorations carried out, attention must be paid to the lessening of chemotactic factors in the blood serum. Throughout his life, the patient suffered pronounced bacterial infectious processes, the last being especially severe and leading rapidly to death.
Case Reports in Dentistry · 2013 · 11 citations · open access
Genetic Mapping in Papillon-Lefèvre Syndrome: A Report of Two Cases
AbstractPapillon-Lefevre syndrome (PLS) is a rare autosomal recessive heterogeneous trait which is characterized by erythematous palmoplantar hyperkeratosis, early-onset periodontitis, and associated calcification of dura mater. The etiology of PLS is multifactorial with genetic, immunological, and microbial factors playing a role in etiopathogenesis. Recently identified genetic defect in PLS has been mapped to chromosome 11q14-q21, which involves mutations of cathepsin C. This paper presents a report of 2 cases of Papillon-lefevre syndrome in which diagnosis is based on clinical presentation and genetic mapping.
International Journal of Dental Research · 2016 · 0 citations · open access
Papillon lefevre syndrome- An imperative role of periodontist
Abstract<p>Papillon Lefevre syndrome (PLS) is a rarely encountered disorder that shows autosomal recessive inheritance. Clinically, it exhibits hyperkeratotic plaques on palmar plantar surfaces, severe periodontal loss and precocious shedding of primary as well as permanent dentition. The reason for this exceptional clinical presentation is vague and speculative. We are reporting one such case of a 23year old female patient.</p>
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
